News & Updates

Show Multimedia Only

IBD patients at high myocarditis risk for up to 20 years

21 Sep 2024

The risk of myocarditis appears to be elevated among patients with inflammatory bowel disease (IBD) for ≥20 years following diagnosis, suggests a study in Sweden. However, absolute risks remain low.

IBD patients at high myocarditis risk for up to 20 years

21 Sep 2024

Culturally adapted lifestyle intervention no better than written materials for CVD risk reduction

19 Sep 2024

Among South Asian adults, a culturally adapted, group-based lifestyle intervention does not appear to result in greater improvements in cardiovascular disease (CVD) risk factors as compared with written health education materials, according to the SAHELI study.

Culturally adapted lifestyle intervention no better than written materials for CVD risk reduction

19 Sep 2024

Pre-cath lab: To fast or not?

19 Sep 2024 by

The SCOFF* trial presented at ESC 2024 shows that fasting is not necessary prior to cardiac catheterization procedures requiring conscious sedation.

Pre-cath lab: To fast or not?

19 Sep 2024

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

19 Sep 2024 by

Advanced age, chronic comorbidity, and immunodeficiency are established risk factors for herpes zoster (HZ). HZ is a debilitating condition that poses a significant burden on patients’ quality of life and the economy and has a bidirectional relationship with cardiovascular disease (CVD). At the 28^th Hong Kong Medical Forum (HKMF), Professor Kai-Hang Yiu of the Department of Medicine, University of Hong Kong, presented an overview of the public health impact of HZ in high-risk patients with immunocompromised conditions or chronic diseases and discussed the long-term effectiveness of adjuvanted recombinant zoster vaccine (RZV) against HZ.

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

19 Sep 2024

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

19 Sep 2024 by

A 39-year-old female hospital porter presented with dyspnoea and Raynaud’s phenomenon in 2010, with no evidence of sclerodactyly. She tested positive for anti-ribonucleoprotein (anti-RNP) and anti–Scl-70 autoantibodies. High-resolution CT (HRCT) of the chest revealed bilateral ground-glass opacities, suggesting interstitial thickening or fibrosis. Echocardiography showed an elevated estimated right ventricular systolic pressure (RVSP) of 74 mm Hg. These findings, along with other defining features, supported a diagnosis of mixed connective tissue disease (MCTD), complicated by interstitial lung disease (ILD) and possibly pulmonary arterial hypertension (PAH).¹

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

19 Sep 2024

Evogliptin does not ease AV calcification, but longer use holds promise

18 Sep 2024

Treatment with evogliptin falls short of providing protective benefits against calcification of the aortic valve (AV), but longer treatment may be helpful, reports a study.

Evogliptin does not ease AV calcification, but longer use holds promise

18 Sep 2024

Single, triple-combo pill hits BP target in two phase III trials

18 Sep 2024 by

GMRx2, a novel low-dose single pill containing three antihypertensive drugs – telmisartan, amlodipine, and indapamide – achieves all efficacy endpoints in two pivotal phase III trials presented at ESC 2024.

Single, triple-combo pill hits BP target in two phase III trials

18 Sep 2024

Vutrisiran may improve outcomes in transthyretin amyloidosis with cardiomyopathy

17 Sep 2024

In patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), treatment with vutrisiran appears to reduce the risk of death from any cause and cardiovascular events while preserving functional capacity and quality of life, as shown in a study.

Vutrisiran may improve outcomes in transthyretin amyloidosis with cardiomyopathy

17 Sep 2024

HELIOS-B shines on vutrisiran for ATTR-CM

16 Sep 2024 by

In the phase III HELIOS-B trial, vutrisiran reduced death and cardiovascular (CV) events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

HELIOS-B shines on vutrisiran for ATTR-CM

16 Sep 2024

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney

15 Sep 2024 by

For atrial fibrillation (AF) patients with normal or impaired renal function, use of nonvitamin K antagonist oral anticoagulants (NOACs) results in improved outcomes relative to vitamin K antagonist (VKA) therapy, suggests a study presented at ESC 2024.

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney

15 Sep 2024

News & Updates

Filter by Specialty:

Specialty:

IBD patients at high myocarditis risk for up to 20 years

IBD patients at high myocarditis risk for up to 20 years

Culturally adapted lifestyle intervention no better than written materials for CVD risk reduction

Culturally adapted lifestyle intervention no better than written materials for CVD risk reduction

Pre-cath lab: To fast or not?

Pre-cath lab: To fast or not?

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

Evogliptin does not ease AV calcification, but longer use holds promise

Evogliptin does not ease AV calcification, but longer use holds promise

Single, triple-combo pill hits BP target in two phase III trials

Single, triple-combo pill hits BP target in two phase III trials

Vutrisiran may improve outcomes in transthyretin amyloidosis with cardiomyopathy

Vutrisiran may improve outcomes in transthyretin amyloidosis with cardiomyopathy

HELIOS-B shines on vutrisiran for ATTR-CM

HELIOS-B shines on vutrisiran for ATTR-CM

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney

NOACs better than VKAs at preventing deaths, CVD in AF patients with or without impaired kidney